Autism Spectrum Disorder (ASD) Clinical Trial
Official title:
A Repeatability and Reproducibility Study of the EarliPoint™ Device in Pediatric Subjects 16-30 Months of Age
The study is a prospective randomized repeatability and reproducibility (R&R) study of the EarliPoint DeviceTM in pediatric subjects 16-30 months of age. The study will enroll subjects who are both clinically-positive and clinically-negative for ASD. The study will be conducted at a single center in the US. The Study consists of a screening period in order to review the subject's medical history to determine subject eligibility, followed by a device administration period during which subjects will undergo testing with the EarliPoint Devices and Expert Clinician Diagnosis (ECD) procedures to determine if they are clinically-positive or clinically-negative for ASD.
Subjects will undergo testing with the same two (2) devices, with one (1) testing session per device per subject, with each testing session yielding three (3) measurements per endpoint per subject, for a total of six (6) measurements per endpoint for each subject enrolled. The order in which the subjects receive testing with each device will be randomized so that the same device is not always used first or last for each subject. The primary objectives of this study are to quantify the repeatability variability and reproducibility variability of all of the EarliPoint device's continuous valued outputs: the underlying continuous score used to classify patients into the binary diagnostic classification of either clinically-positive or clinically-negative for autism spectrum disorder (ASD) as well as each of the three EarliPoint Device severity scores (the social disability index, verbal ability index, and nonverbal ability index). The secondary objectives of this study are to quantify the repeatability and reproducibility variability in producing each of the three EarliPoint Device severity scores: the social disability index, verbal ability index, and nonverbal ability index. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03715166 -
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
|
Phase 3 | |
Not yet recruiting |
NCT05182697 -
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
Completed |
NCT02803801 -
Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers
|
N/A | |
Recruiting |
NCT04376151 -
Guided ACT and for Adults With ASD
|
N/A | |
Terminated |
NCT03715153 -
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
|
Phase 3 | |
Terminated |
NCT01592773 -
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
Withdrawn |
NCT01395953 -
Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders
|
Phase 2 | |
Terminated |
NCT01248130 -
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
|
Phase 2 | |
Completed |
NCT04299464 -
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
Recruiting |
NCT03392870 -
Evaluation of a Clinical Transitional Program in Autism
|
N/A | |
Completed |
NCT01592786 -
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
Enrolling by invitation |
NCT05187377 -
A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism
|
Phase 2 | |
Completed |
NCT04631432 -
Choice Switching and Autism
|
||
Recruiting |
NCT04578756 -
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
|
Phase 3 | |
Recruiting |
NCT06443320 -
Evaluation of the Videodrama Therapeutic Device for Children With Autism Spectrum Disorders
|
N/A | |
Completed |
NCT02037022 -
Pivotal Response Treatment Package for Young Children With Autism
|
N/A | |
Completed |
NCT01854346 -
Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders
|
N/A | |
Active, not recruiting |
NCT04895215 -
AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
Active, not recruiting |
NCT03426826 -
The Gut-Brain Study
|
Phase 1 | |
Completed |
NCT02384486 -
Efficacy of Training Programme to Reduce Stress
|
N/A |